Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Short Interest Ratio & Short Volume

Celldex Therapeutics logo
$42.61 -2.26 (-5.04%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$42.59 -0.02 (-0.05%)
As of 08/13/2026 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Celldex Therapeutics Short Interest Overview

As of July 31, 2026, Celldex Therapeutics (CLDX) had a short interest of 7.63 million shares sold short, representing 10.25% of the public float. This marks a -0.47% decrease in short interest since the prior report. The short interest ratio (days to cover) is 7.6, meaning it would take 7.6 days of the average trading volume of 1.02 million shares to cover all short positions.

Current Short Interest
7,627,081 shares
Previous Short Interest
7,663,191 shares
Change Vs. Previous Month
-0.47%
Dollar Volume Sold Short
$290.29 million
Short Interest Ratio
7.6 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
78,530,000 shares
Short Percent of Float
10.25%
Today's Trading Volume
670,859 shares
Average Trading Volume
1,019,787 shares
Today's Volume Vs. Average
66%
Short Selling Celldex Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Celldex Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CLDX Short Interest Over Time

CLDX Days to Cover Over Time

CLDX Percentage of Float Shorted Over Time

Celldex Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/20267,627,081 shares $290.29 million -0.5%10.3%7.62 $38.06
7/15/20267,663,191 shares $293.58 million -1.0%10.3%9.14 $38.31
6/30/20267,738,673 shares $287.96 million +6.1%10.4%4.3 $37.21
6/15/20267,295,393 shares $234.33 million +2.1%9.8%9.05 $32.12
5/29/20267,144,877 shares $224.56 million +0.2%9.6%10.73 $31.43
5/15/20267,130,776 shares $223.48 million -6.2%9.6%10.06 $31.34
4/30/20267,599,353 shares $249.87 million -8.5%10.2%9.41 $32.88
4/15/20268,309,099 shares $281.43 million -8.5%11.2%5.54 $33.87
3/31/20269,075,800 shares $287.88 million -1.8%12.2%8.49 $31.72
3/13/20269,237,012 shares $272.58 million +2.6%14.5%9.95 $29.51
2/27/20269,006,071 shares $270.99 million -1.9%12.1%8.44 $30.09
2/13/20269,181,713 shares $211.18 million -0.6%12.3%13.3 $23.00
1/30/20269,237,135 shares $227.23 million +2.2%14.5%19.42 $24.60
1/15/20269,034,401 shares $232.09 million +9.6%14.2%10.84 $25.69
12/31/20258,244,450 shares $223.92 million +20.1%13.0%12.26 $27.16
12/15/20256,865,432 shares $185.98 million -20.9%10.8%7.9 $27.09
11/28/20258,675,509 shares $234.20 million -1.9%13.7%13.27 $27.00
11/14/20258,845,278 shares $226.00 million +17.8%13.9%8.49 $25.55
10/31/20257,509,487 shares $200.73 million +1.5%11.8%10.41 $26.73
10/15/20257,400,000 shares $202.32 million +4.5%11.7%6.1 $27.34
9/30/20257,080,000 shares $183.16 million +7.6%N/A5.9 $25.87
9/15/20256,580,000 shares $161.21 million -8.7%N/A5.2 $24.50
8/31/20257,210,000 shares $159.20 million -1.4%11.4%5.7 $22.08
8/15/20257,310,000 shares $186.41 million -6.0%N/A6.1 $25.50
7/31/20257,780,000 shares $171.00 million -8.2%12.3%7.5 $21.98
7/15/20258,470,000 shares $193.54 million +7.6%N/A8.6 $22.85
6/30/20257,870,000 shares $160.15 million +0.5%12.4%7.9 $20.35
6/15/20257,830,000 shares $166.47 million -6.5%12.3%8.3 $21.26
5/31/20258,370,000 shares $163.13 million -8.3%13.1%9.6 $19.49
5/15/20259,130,000 shares $183.51 million +1.3%14.3%11.3 $20.10
4/30/20259,010,000 shares $187.68 million +2.6%N/A11.6 $20.83
4/15/20258,780,000 shares $161.29 million +5.8%13.8%11 $18.37
3/31/20258,300,000 shares $150.65 million -9.3%13.0%9.3 $18.15
3/15/20259,150,000 shares $186.84 million +3.0%14.3%10.5 $20.42
2/28/20258,880,000 shares $182.66 million -3.4%13.9%9.7 $20.57
2/15/20259,190,000 shares $208.61 million +3.6%14.4%9.8 $22.70
1/31/20258,870,000 shares $217.23 million +4.6%N/A8.8 $24.49
1/15/20258,480,000 shares $191.82 million +4.8%N/A8.2 $22.62
12/31/20248,090,000 shares $204.43 million +10.7%N/A8 $25.27
12/15/20247,310,000 shares $185.75 million -5.1%N/A6 $25.41
A $2 trillion fund just sounded the alarm (Ad)

Norway's roughly $2 trillion sovereign wealth fund holds massive stakes in Nvidia, Apple and SpaceX. Its CEO now says markets are behaving abnormally. Meanwhile, Anthropic signed a 20-year, $9.1 billion data center deal with Riot Platforms, redirecting 191 megawatts of capacity toward its AI ambitions, according to CNBC. A little-known publicly traded company counts Anthropic as its largest holding, offering ordinary investors a potential backdoor before any IPO.tc pixel

Discover the Anthropic backdoor ticker before wider markets notice.
11/30/20247,700,000 shares $211.29 million -1.7%N/A6.5 $27.44
11/15/20247,830,000 shares $184.40 million -5.0%N/A6.8 $23.55
10/31/20248,240,000 shares $214.73 million -1.9%N/A7.7 $26.06
10/15/20248,400,000 shares $246.96 million +1.1%N/A8.3 $29.40
9/30/20248,310,000 shares $282.46 million -1.2%N/A8.5 $33.99
9/15/20248,410,000 shares $371.39 million -1.9%N/A11.4 $44.16
8/31/20248,570,000 shares $354.20 million -1.0%N/A12.2 $41.33
8/15/20248,660,000 shares $286.65 million +3.1%N/A12.2 $33.10
7/31/20248,400,000 shares $320.12 million +13.7%N/A12.1 $38.11
7/15/20247,390,000 shares $292.27 million +5.7%N/A11.5 $39.55
6/30/20246,990,000 shares $258.70 million +8.7%N/A10.9 $37.01
6/15/20246,430,000 shares $222.93 million +2.6%N/A10.1 $34.67
5/31/20246,270,000 shares $208.79 million -5.3%N/A9.1 $33.30
5/15/20246,620,000 shares $265.93 million -5.3%N/A7.4 $40.17
4/30/20246,990,000 shares $261.57 million +3.6%N/A7.7 $37.42
4/15/20246,750,000 shares $263.72 million +2.9%N/A7.3 $39.07
3/31/20246,560,000 shares $275.32 million +11.2%N/A6.9 $41.97
3/15/20245,900,000 shares $247.86 million -8.0%N/A6.4 $42.01
2/29/20246,410,000 shares $308.06 million -7.6%N/A7.4 $48.06
2/15/20246,940,000 shares $255.39 million +3.4%N/A9.3 $36.80
1/31/20246,710,000 shares $236.33 million +7.9%N/A8.5 $35.22
1/15/20246,220,000 shares $261.49 million -5.6%N/A7.6 $42.04
12/31/20236,590,000 shares $261.36 million -10.3%N/A8.6 $39.66
12/15/20237,350,000 shares $273.05 million -8.9%N/A9.6 $37.15
11/30/20238,070,000 shares $243.79 million +2.4%N/A11.1 $30.21
11/15/20237,880,000 shares $224.82 million +40.2%N/A11.3 $28.53
10/31/20235,620,000 shares $132.18 million +0.9%N/A9.2 $23.52
10/15/20235,570,000 shares $145.60 million -3.3%N/A12.1 $26.14
9/30/20235,760,000 shares $158.52 million -5.4%N/A13.1 $27.52
9/15/20236,090,000 shares $170.22 million -3.3%N/A14.3 $27.95
8/31/20236,300,000 shares $175.77 million -3.7%N/A13.5 $27.90
8/15/20236,540,000 shares $205.55 million +8.5%N/A14.3 $31.43
7/31/20236,030,000 shares $213.22 million -3.8%N/A13.8 $35.36
7/15/20236,270,000 shares $233.81 million +1.8%N/A13.5 $37.29
6/30/20236,160,000 shares $209.01 million +2.7%N/A11 $33.93
6/15/20236,000,000 shares $221.22 million +3.5%N/A9.8 $36.87
5/31/20235,800,000 shares $184.44 million +7.0%N/A9.3 $31.80
5/15/20235,420,000 shares $185.69 million +1.1%N/A8.4 $34.26
4/30/20235,360,000 shares $168.52 million +3.5%N/A8.4 $31.44
4/15/20235,180,000 shares $156.90 million -1.7%N/A8.6 $30.29
3/31/20235,270,000 shares $189.61 million +38.0%N/A9.9 $35.98
3/15/20233,820,000 shares $167.13 million +5.5%N/A8 $43.75
2/28/20233,620,000 shares $154.90 million +4.3%N/A7.5 $42.79
2/15/20233,470,000 shares $148.79 million +4.5%N/A7.7 $42.88
1/31/20233,320,000 shares $146.28 million -4.3%N/A6.8 $44.06
1/15/20233,470,000 shares $159.69 million +1.8%N/A7 $46.02
12/30/20223,410,000 shares $151.98 million -17.2%N/A6.8 $44.57
12/15/20224,120,000 shares $182.47 million +1.7%N/A8 $44.29
11/30/20224,050,000 shares $150.21 million -1.9%N/A9 $37.09
11/15/20224,130,000 shares $151.53 million -8.2%N/A9 $36.69
Elon’s S-1 Master Plan Could Rewrite the Rules of AI (Ad)

A researcher who has advised Goldman Sachs, JPMorgan Chase, BlackRock, and Fidelity flew to Starbase after spotting a detail buried inside SpaceX's S-1 filing. Rob Spivey, Managing Director at Altimetry, says the discovery could reshape how investors view the AI economy, and he's naming the one stock positioned to benefit, not Tesla or SpaceX. The full briefing and stock name are free, with no credit card required.tc pixel

Get the free briefing and stock name today
10/31/20224,500,000 shares $158.09 million -0.9%N/A9.7 $35.13
10/15/20224,540,000 shares $142.74 million -1.5%N/A9.3 $31.44
9/30/20224,610,000 shares $129.59 million +2.4%N/A9 $28.11
9/15/20224,500,000 shares $136.40 million +2.3%N/A6.2 $30.31
8/31/20224,400,000 shares $133.76 million +4.0%N/A5.6 $30.40
8/15/20224,230,000 shares $158.92 million +14.3%N/A5.1 $37.57
7/31/20223,700,000 shares $113.66 million -2.9%30.7%4.3 $30.72
7/15/20223,810,000 shares $111.79 million -0.3%31.6%4.5 $29.34
6/30/20223,820,000 shares $102.99 million -18.9%31.7%4.7 $26.96
6/15/20224,710,000 shares $104.99 million +1.5%39.0%7.3 $22.29
5/31/20224,640,000 shares $109.13 million -5.5%N/A8 $23.52
5/15/20224,910,000 shares $147.25 million -1.0%N/A8.7 $29.99
4/30/20224,960,000 shares $151.53 million -9.3%N/A9 $30.55
4/15/20225,470,000 shares $196.04 million -0.2%N/A9.8 $35.84
3/31/20225,480,000 shares $186.65 million -8.7%N/A9.3 $34.06
3/15/20226,000,000 shares $187.26 million +3.3%N/A10.3 $31.21
2/28/20225,810,000 shares $173.72 million +11.7%N/A10 $29.90
2/15/20225,200,000 shares $169.78 million +2.4%N/A9.4 $32.65
1/31/20225,080,000 shares $157.53 million +3.3%N/A9.9 $31.01
1/15/20224,920,000 shares $157.00 million +3.1%N/A0 $31.91
12/31/20214,770,000 shares $184.31 million +9.9%N/A10.6 $38.64
12/15/20214,340,000 shares $166.92 million +6.6%N/A10.1 $38.46
11/30/20214,070,000 shares $155.07 million +12.4%N/A9.7 $38.10
11/15/20213,620,000 shares $155.70 million -2.7%N/A8.2 $43.01
10/29/20213,720,000 shares $158.25 million +25.7%N/A7.9 $42.54
10/15/20212,960,000 shares $136.69 million -0.7%N/A5.7 $46.18
9/30/20212,980,000 shares $160.89 million -11.0%N/A3.8 $53.99
9/15/20213,350,000 shares $178.25 million -15.4%N/A3.7 $53.21
8/31/20213,960,000 shares $208.49 million -8.1%N/A4.4 $52.65

CLDX Short Interest - Frequently Asked Questions

Short interest is the volume of Celldex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 7,627,081 shares of CLDX short. 10.25% of Celldex Therapeutics' shares are currently sold short. Learn More on Celldex Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLDX shares currently have a short interest ratio of 7.6. Learn More on Celldex Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.25% of Celldex Therapeutics' floating shares are currently sold short.

Celldex Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 7,627,081 shares, a decline of 0.5% from the previous total of 7,663,191 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

10.25% of Celldex Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Celldex Therapeutics: BioMarin Pharmaceutical Inc. (6.50%), Madrigal Pharmaceuticals, Inc. (10.33%), Abivax SA Sponsored ADR (5.95%), Summit Therapeutics PLC (27.54%), Halozyme Therapeutics, Inc. (12.67%), Nuvalent, Inc. (0.95%), Cytokinetics, Incorporated (12.63%), Krystal Biotech, Inc. (12.45%), Ionis Pharmaceuticals, Inc. (13.16%), Spyre Therapeutics, Inc. (16.38%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling CLDX is an investing strategy that aims to generate trading profit from Celldex Therapeutics as its price is falling. CLDX shares are trading down $2.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Celldex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDX, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CLDX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:CLDX is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Elon’s S-1 Master Plan Could Rewrite the Rules of AI
A researcher who has advised Goldman Sachs, JPMorgan Chase, BlackRock, and Fidelity flew to Starbase after spo...
Altimetry | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
A $2 trillion fund just sounded the alarm
Norway's roughly $2 trillion sovereign wealth fund holds massive stakes in Nvidia, Apple and SpaceX. Its CEO n...
The Oxford Club | Sponsoredtc pixel
The trading strategy that works BECAUSE you have a life
Tim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day. It's not ...
Tim Sykes | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel